The GAVI vaccine alliance has stated that the first of nearly 100 million doses of US pharmaceutical company Johnson & Johnson's (J&J) (NYSE:JNJ) COVID-19 vaccine being donated by the European Union by year-end have begun arriving in African countries, Reuters news agency reported on Monday.
GAVI, which leads the COVAX vaccine sharing facility, said that this deal was negotiated as part of the bloc's overall pledge to share at least 500 million doses with low and lower-middle income countries by mid-2022.
Ursula von der Leyen, European Commission president, was quoted as saying: "The first doses have reached Niger, with more doses arriving in a number of countries this week."
The commission's statement also listed Guinea Conakry, Mauritania, the Central African Republic, Djibouti, Nigeria, Togo and the Republic of Congo.
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
BD receives FDA clearance for Surgiphor 1000mL irrigation system
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
FDA accepts rusfertide NDA and grants priority review for polycythemia vera